AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15612616 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of fluconazole 200 mg
Number of subjects: 24
Study 11352452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tefilcon contact lenses
Number of subjects: 8
Study 11352452 — intervention group
Group type: EXPERIMENTAL
Intervention: Vifilcon contact lenses
Number of subjects: 8
Study 11352452 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 8
Study 11352452 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lipid
Number of subjects: 8
Study 11352452 — intervention group
Group type: EXPERIMENTAL
Intervention: Triolein (largest lipid extracted)
Number of subjects: 8
Study 11352452 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller lipids
Number of subjects: 8
Study 8919737 — intervention group
Group type: EXPERIMENTAL
Intervention: VIDAS enzyme linked fluorescent assay
Number of subjects: 430
Study 8919737 — intervention group
Group type: COMPARATOR
Intervention: Chlamydiazyme
Number of subjects: 430
Study 8919737 — intervention group
Group type: COMPARATOR
Intervention: Polymerase chain reaction
Number of subjects: 430
Study 1920229 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding after 4 hours
Number of subjects: 100
Study 1920229 — intervention group
Group type: COMPARATOR
Intervention: Feeding after 18 hours
Number of subjects: 100
Study 6195795 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for advanced and metastatic bladder carcinomas
Number of subjects: 0
Study 6195795 — intervention group
Group type: EXPERIMENTAL
Intervention: Local chemotherapy (doxorubicin) for carcinoma in situ
Number of subjects: 0
Study 6195795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy after complete transurethral resection of superficial bladder tumors
Number of subjects: 0
Study 6195795 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy following radical surgery or radiotherapy
Number of subjects: 0
Study 30712728 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 3 drops of 4% rose essential oil for 10 minutes one night and one hour before surgery
Number of subjects: 66
Study 30712728 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study 27874971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 1000 mg intravenous infusion
Number of subjects: 0
Study 25684224 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam (LEV)
Number of subjects: 359
Study 25684224 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-released carbamazepine (CR-CBZ)
Number of subjects: 359
Study 25684224 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (LTG)
Number of subjects: 359
Study 24647908 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhomogeneous static magnetic field (SMF) exposure for 30 minutes after RWPE challenge
Number of subjects: 0
Study 24647908 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated SMF exposure (on 3 consecutive days) after RWPE challenge
Number of subjects: 0
Study 24647908 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged SMF exposure (60 minutes) after RWPE challenge
Number of subjects: 0
Study 24647908 — intervention group
Group type: EXPERIMENTAL
Intervention: SMF exposure
Number of subjects: 0
Study 22568738 — intervention group
Group type: EXPERIMENTAL
Intervention: Suburban Area (SA) adolescents
Number of subjects: 332
Study 22568738 — intervention group
Group type: EXPERIMENTAL
Intervention: Downtown Area (DA) adolescents
Number of subjects: 332
Study 19944392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydration (1000mL of 0.9% saline infusion)
Number of subjects: 201
Study 19944392 — intervention group
Group type: COMPARATOR
Intervention: No additional hydration (control group)
Number of subjects: 201
Study 18158690 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of vitamin E
Number of subjects: 36
Study 18158690 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of vitamin C
Number of subjects: 36
Study 18158690 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of vitamin E and 1000 mg of vitamin C
Number of subjects: 36
Study 18158690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 14693597 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg/kg followed by cisatracurium 0.03 mg/kg
Number of subjects: 60
Study 14693597 — intervention group
Group type: EXPERIMENTAL
Intervention: cisatracurium 0.15 mg/kg followed by cisatracurium 0.03 mg/kg
Number of subjects: 60
Study 14693597 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg/kg followed by rocuronium 0.15 mg/kg
Number of subjects: 60
Study 11858491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (60 mg p.o.)
Number of subjects: 54
Study 11858491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (120 IU/kg s.c.)
Number of subjects: 54
Study 11858491 — intervention group
Group type: COMPARATOR
Intervention: Control (water p.o.)
Number of subjects: 54
Study 9400450 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil alpha‐cyclodextrin
Number of subjects: 156
Study 9400450 — intervention group
Group type: COMPARATOR
Intervention: Moxisylyte chlorhydrate
Number of subjects: 156
Study 9375234 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere (LH) stimulation
Number of subjects: 14
Study 9375234 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere (RH) stimulation
Number of subjects: 14
Study 2193712 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderal LA 160 mg daily
Number of subjects: 51
Study 2193712 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-Inderal LA 80 mg daily
Number of subjects: 51
Study 454094 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (6 mg of delta‐9‐tetrahydrocannabinol)
Number of subjects: 20
Study 454094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31768868 — intervention group
Group type: EXPERIMENTAL
Intervention: LRYGB
Number of subjects: 278
Study 31768868 — intervention group
Group type: COMPARATOR
Intervention: LSG
Number of subjects: 278
Study 31289281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaly device
Number of subjects: 100
Study 27070868 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of Amplification of Error (MAE)
Number of subjects: 30
Study 27070868 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Instruction (DI)
Number of subjects: 30
Study 27070868 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 25966363 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (12-week supervised program, 5 days/week, 1 h/day, 80-85% of maximum heart rate)
Number of subjects: 24
Study 25966363 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 24
Study 24020372 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN)
Number of subjects: 40
Study 24020372 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient restriction
Number of subjects: 40
Study 24020372 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 21843084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gordonia bronchialis
Number of subjects: 0
Study 21843084 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodococcus coprophilus
Number of subjects: 0
Study 21843084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19689921 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (up to 300 mg/d)
Number of subjects: 35
Study 19689921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 17381567 — intervention group
Group type: EXPERIMENTAL
Intervention: Jugular vein compression during epidural catheter placement
Number of subjects: 20
Study 17381567 — intervention group
Group type: COMPARATOR
Intervention: Jugular vein compression after catheter withdrawal
Number of subjects: 20
Study 15502050 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX 5 mg/kg IV infusion before anesthesia induction
Number of subjects: 40
Study 15502050 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40
Study 11436936 — intervention group
Group type: EXPERIMENTAL
Intervention: Message Group
Number of subjects: 266
Study 11436936 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 266
Study 9143068 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised weight-training program three times a week
Number of subjects: 32
Study 9143068 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 32
Study 8203209 — intervention group
Group type: EXPERIMENTAL
Intervention: Random dot pattern (ROKN)
Number of subjects: 30
Study 8203209 — intervention group
Group type: COMPARATOR
Intervention: Wide interval stripe pattern (SOKN)
Number of subjects: 30
Study 3102858 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-1-preserved erythrocytes
Number of subjects: 0
Study 3102858 — intervention group
Group type: COMPARATOR
Intervention: Whole blood
Number of subjects: 0
Study 28987470 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 long chain‐PUFA (2.9 g/day)
Number of subjects: 36
Study 28987470 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (placebo)
Number of subjects: 36
Study 27751832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneal pressure (PP) of 6-8 mmHg (Group I)
Number of subjects: 46
Study 27751832 — intervention group
Group type: COMPARATOR
Intervention: Pneumoperitoneal pressure (PP) of 9-10 mmHg (Group II)
Number of subjects: 46
Study 25693783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 25 mg
Number of subjects: 142
Study 25693783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 75 mg
Number of subjects: 142
Study 25693783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 150 mg
Number of subjects: 142
Study 25693783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 25693783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (all doses) in OLE at week 48
Number of subjects: 142
Study 22147903 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe combination
Number of subjects: 1533
Study 19077131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine or venlafaxine (n = 30)
Number of subjects: 58
Study 19077131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 28)
Number of subjects: 58
Study 17229251 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-mediated intervention (daily orientation, therapeutic activities, feeding and hydration assistance, vision and hearing protocols)
Number of subjects: 37
Study 17229251 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 37
Study 15764421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan + contingent vouchers
Number of subjects: 199
Study 15764421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan + non-contingent vouchers
Number of subjects: 199
Study 15764421 — intervention group
Group type: COMPARATOR
Intervention: Placebo + contingent vouchers
Number of subjects: 199
Study 15764421 — intervention group
Group type: COMPARATOR
Intervention: Placebo + non-contingent vouchers
Number of subjects: 199
Study 11913803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 100
Study 11913803 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 100
Study 9440743 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant external-beam radiation therapy (XRT)
Number of subjects: 141
Study 9440743 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control group for low-grade lesions)
Number of subjects: 141
Study 8206471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic clotrimazole 500 mg ovule just before or on the last day of the menses each month for 6 months
Number of subjects: 23
Study 8206471 — intervention group
Group type: COMPARATOR
Intervention: Empiric self-treatment with clotrimazole 500 mg ovule at the onset of symptoms for 6 months
Number of subjects: 23
Study 8206471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic clotrimazole
Number of subjects: 23
Study 8206471 — intervention group
Group type: COMPARATOR
Intervention: Empiric self-treatment
Number of subjects: 23
Study 8206471 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for regimen
Number of subjects: 23
Study 2914540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sennosides (30 mg orally at 7:00 PM)
Number of subjects: 7
Study 2914540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral administration)
Number of subjects: 7
Study 4736626 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilboestrol 1 mg daily
Number of subjects: 16
Study 4736626 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilboestrol 7.5 mg daily
Number of subjects: 16
Study 4736626 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilboestrol 15 mg daily
Number of subjects: 16
Study 4736626 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens (Premarin) 15 mg daily
Number of subjects: 16
Study 4736626 — intervention group
Group type: COMPARATOR
Intervention: Various oestrogen regimens
Number of subjects: 16
Study 31974099 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid insulin-and-pramlintide artificial pancreas
Number of subjects: 112
Study 31974099 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular insulin-and-pramlintide artificial pancreas
Number of subjects: 112
Study 31974099 — intervention group
Group type: COMPARATOR
Intervention: Rapid insulin-alone artificial pancreas
Number of subjects: 112
Study 31776293 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06427878 1500 milligrams per day
Number of subjects: 63
Study 31776293 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 63
Study 30014661 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion combined with 5‐HT receptor antagonist
Number of subjects: 58
Study 30014661 — intervention group
Group type: COMPARATOR
Intervention: 5‐HT receptor antagonist (control group)
Number of subjects: 58
Study 27135149 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (moderately high dose), starting at least six hours pre-PCI and continued for 28 days post-PCI
Number of subjects: 315
Study 27135149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 27135149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt chromium (CoCr) alloy stents
Number of subjects: 315
Study 27135149 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel (SS) alloy stents
Number of subjects: 315
Study 24354833 — intervention group
Group type: EXPERIMENTAL
Intervention: Durham Connects (intervention)
Number of subjects: 4777
Study 22992074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 6026
Study 22992074 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia
Number of subjects: 6026
Study 22992074 — intervention group
Group type: COMPARATOR
Intervention: No hypoglycemia
Number of subjects: 6026
Study 22992074 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoglycemia (>1 day)
Number of subjects: 6026
Study 22992074 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoglycemia without insulin treatment
Number of subjects: 6026
Study 22992074 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoglycemia
Number of subjects: 6026
Study 22992074 — intervention group
Group type: EXPERIMENTAL
Intervention: Death from distributive shock
Number of subjects: 6026
Study 19927026 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (Q; 1000 mg x d(‐1))
Number of subjects: 26
Study 17115179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonexercise prediction models using thigh skeletal muscle mass and cardiac dimensions
Number of subjects: 60
Study 17115179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonexercise prediction models using left ventricular internal dimensions and stroke volume
Number of subjects: 60
Study 17115179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonexercise prediction models applied to the validation group
Number of subjects: 60
Study 16293869 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel 35 mg/m2 on days 1, 8, and 15 for < or = eight cycles
Number of subjects: 215
Study 16293869 — intervention group
Group type: COMPARATOR
Intervention: 3‐weekly docetaxel 75 mg/m2 on day 1 every 3 weeks for < or = eight cycles
Number of subjects: 215
Study 11916776 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC‐201 (0.6, 0.9, 1.2, 1.5, 2.0, or 2.5 g/kg of body weight)
Number of subjects: 81
Study 11916776 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 81
Study 11916776 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC‐201
Number of subjects: 81
Study 9588719 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cm margin of resection for melanomas up to 2 mm thick
Number of subjects: 0
Study 9588719 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cm margin of resection for melanomas 1 to 4 mm thick
Number of subjects: 0
Study 9588719 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cm margin of resection for melanomas thicker than 4 mm
Number of subjects: 0
Study 7639505 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Hydrochlorothiazide (20 mg/12.5 mg)
Number of subjects: 26
Study 7639505 — intervention group
Group type: COMPARATOR
Intervention: Captopril + Hydrochlorothiazide (50 mg/25 mg)
Number of subjects: 26
Study 2666455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 111
Study 2666455 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 111
Study 2666455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 736633 — intervention group
Group type: EXPERIMENTAL
Intervention: EE2 (0.25 mg starting dose)
Number of subjects: 30
Study 736633 — intervention group
Group type: COMPARATOR
Intervention: E3 (2 mg starting dose)
Number of subjects: 30
Study 736633 — intervention group
Group type: COMPARATOR
Intervention: E3-suc (2.5 mg starting dose)
Number of subjects: 30
Study 736633 — intervention group
Group type: EXPERIMENTAL
Intervention: EE2 followed by E3 or E3-suc
Number of subjects: 30
Study 736633 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin
Number of subjects: 30
Study 31492643 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered telephone CBT
Number of subjects: 558
Study 31492643 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CBT with minimal therapist support
Number of subjects: 558
Study 31492643 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 558
Study 30033974 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (LVFX) 500 mg
Number of subjects: 411
Study 30033974 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin (STFX)
Number of subjects: 411
Study 30033974 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LVFX and STFX
Number of subjects: 411
Study 26360083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) intervention, 6 sessions over 8 weeks added to standard care
Number of subjects: 150
Study 26360083 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 150
Study 23592683 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional school-based lifestyle intervention including a playful physical activity program and lessons on nutrition, media use, and sleep.
Number of subjects: 652
Study 21981813 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward-viewing echoendoscope
Number of subjects: 58
Study 21981813 — intervention group
Group type: COMPARATOR
Intervention: Oblique-viewing echoendoscope
Number of subjects: 58
Study 18781660 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 107
Study 18781660 — intervention group
Group type: EXPERIMENTAL
Intervention: PE combined with Cognitive Restructuring (PE/CR)
Number of subjects: 107
Study 18781660 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 107
Study 18781660 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) and PE/CR
Number of subjects: 107
Study 17446716 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral and topical administration of lutein and zeaxanthin
Number of subjects: 0
Study 17446716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of lutein
Number of subjects: 0
Study 17446716 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of lutein and zeaxanthin
Number of subjects: 0
Study 17446716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of zeaxanthin
Number of subjects: 0
Study 15023936 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg (C8)
Number of subjects: 16
Study 15023936 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg (C16)
Number of subjects: 16
Study 15023936 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg (V80)
Number of subjects: 16
Study 15023936 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized index of renin release (renin/pharmacokinetic index)
Number of subjects: 16
Study 11772257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast (up to 15 mg)
Number of subjects: 0
Study 11772257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast
Number of subjects: 0
Study 9834003 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐188494 (PO2)
Number of subjects: 16
Study 9834003 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐187745 (PO1)
Number of subjects: 16
Study 9834003 — intervention group
Group type: COMPARATOR
Intervention: Model-independent AUC method
Number of subjects: 16
Study 8158682 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma alpha-linolenic acid levels
Number of subjects: 240
Study 8158682 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma linoleic acid levels
Number of subjects: 240
Study 8158682 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating red meat at least five times per week
Number of subjects: 240
Study 2906863 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement for abstinence from illicit drug use
Number of subjects: 16